List of Excipients in Branded Drug HUMALOG

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	HUMALOG	insulin lispro	50090-4488	GLYCERIN
A-S Medication Solutions	HUMALOG	insulin lispro	50090-4488	HYDROCHLORIC ACID
A-S Medication Solutions	HUMALOG	insulin lispro	50090-4488	METACRESOL
A-S Medication Solutions	HUMALOG	insulin lispro	50090-4488	PHENOL
A-S Medication Solutions	HUMALOG	insulin lispro	50090-4488	SODIUM HYDROXIDE
A-S Medication Solutions	HUMALOG	insulin lispro	50090-4488	SODIUM PHOSPHATE, DIBASIC
A-S Medication Solutions	HUMALOG	insulin lispro	50090-4488	WATER

HUMALOG Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 9, 2026

Humalog is insulin lispro, a rapid-acting recombinant insulin marketed by Eli Lilly in U-100, U-200, and premixed formulations. Its core excipient system is mature, widely understood, and largely unprotected by meaningful composition-of-matter exclusivity. The strongest commercial opportunities are therefore in biosimilar and follow-on insulin manufacturing, concentrated delivery, device compatibility, preservative and container systems, global supply, and differentiated premix or pump formulations.

The principal excipients in Humalog are glycerol, phosphate buffer, metacresol, zinc, and water. Premixed products add protamine to create the intermediate-acting insulin lispro protamine component. These excipients support insulin stability, antimicrobial preservation, zinc-mediated molecular association, and suspension performance.

What excipients are used in Humalog formulations?

Humalog uses a conventional excipient platform that has been commercially validated for more than two decades.

Product	Active insulin	Principal excipients and formulation functions
Humalog U-100 injection	Insulin lispro, 100 units/mL	Glycerol, dibasic sodium phosphate, metacresol, zinc oxide, water, pH adjusters
Humalog U-200 KwikPen	Insulin lispro, 200 units/mL	Glycerol, metacresol, zinc, water, pH adjusters; higher concentration reduces injection volume
Humalog Mix 75/25	25% insulin lispro and 75% insulin lispro protamine suspension	Glycerol, phosphate, metacresol, phenol, zinc, protamine sulfate, water, pH adjusters
Humalog Mix 50/50	50% insulin lispro and 50% insulin lispro protamine suspension	Similar protamine, preservative, buffer, and zinc system
Lyumjev comparator	Insulin lispro-aabc	Uses citrate and treprostinil-related absorption technology rather than the standard Humalog excipient system

FDA labeling identifies glycerol, phosphate, metacresol, zinc, and water as key components of Humalog U-100. The premixed products use protamine sulfate to form insulin lispro protamine crystals and extend absorption after injection (FDA, 2023a; FDA, 2023b).

What does each Humalog excipient do?

Glycerol provides tonicity control and helps maintain the solution environment. Dibasic sodium phosphate contributes buffering capacity and supports pH control. Metacresol is the primary antimicrobial preservative in the soluble formulation. Zinc promotes insulin association and helps control the physical state of the protein. In premixed products, protamine binds insulin lispro and creates an intermediate-acting depot.

The system is commercially important because changing one excipient can affect several quality attributes at once:

• insulin aggregation and fibril formation;
• potency and related substances;
• preservative effectiveness;
• adsorption to glass, elastomer, or plastic surfaces;
• injection pain and local tolerability;
• pump compatibility;
• suspension settling and resuspendability;
• container closure integrity;
• stability after first use.

How does Humalog’s excipient strategy compare with competing insulin products?

Humalog’s excipient strategy is similar to other rapid-acting insulin analogs but differs in its use of delivery-enhancing technology.

Product	Manufacturer	Active ingredient	Distinguishing formulation approach
Humalog	Eli Lilly	Insulin lispro	Conventional glycerol, phosphate, metacresol, zinc platform
Admelog	Sanofi	Insulin lispro	Follow-on insulin lispro using a comparable biological and excipient framework
NovoLog/NovoRapid	Novo Nordisk	Insulin aspart	Conventional rapid-acting insulin formulation with phenol, metacresol, zinc, and buffer components
Fiasp	Novo Nordisk	Insulin aspart	Adds niacinamide and arginine to accelerate absorption and improve formulation behavior
Lyumjev	Eli Lilly	Insulin lispro-aabc	Uses citrate and treprostinil-related technology for faster absorption
Apidra	Sanofi	Insulin glulisine	Uses a distinct analog and excipient system, including polysorbate-related formulation elements

Fiasp and Lyumjev demonstrate that excipients can create clinically meaningful differentiation after the underlying insulin analog is mature. Their commercial positioning depends less on preserving the original Humalog formula and more on improving onset, pump use, post-meal control, or injection convenience.

What commercial opportunities exist for Humalog excipients?

1. Biosimilar and follow-on insulin lispro supply

The largest opportunity is supplying excipients and formulation services to insulin lispro competitors. Admelog was approved by FDA in 2017 as a follow-on insulin lispro product under the then-applicable pathway. After the March 2020 transition of insulin products to the biologics framework, insulin lispro competitors can use the 351(k) biosimilar pathway or other applicable biologics routes (FDA, 2017; FDA, 2020).

A supplier with qualified grades of metacresol, glycerol, phosphate, zinc, protamine, or container components can target:

• insulin lispro biosimilars;
• regional human-insulin products;
• premixed insulin products;
• hospital and pen-fill presentations;
• contract manufacturing organizations producing cartridges or vials.

The value proposition is not simply low cost. Insulin manufacturers require lot-to-lot consistency, low endotoxin burden, validated microbial control, and reliable global supply.

2. High-concentration insulin formulations

Humalog U-200 shows the commercial value of concentration-based lifecycle management. A U-200 product delivers the same insulin dose in half the injection volume, which can improve usability for patients requiring high daily doses.

Excipient opportunities include systems that maintain stability at higher protein concentration without increasing:

• aggregation;
• viscosity;
• opalescence;
• injection force;
• adsorption;
• preservative instability.

High-concentration products require specialized analytical development. Excipient suppliers that can provide data on protein interaction, viscosity, subvisible particles, and device compatibility have stronger commercial relevance than commodity suppliers.

3. Pump-compatible insulin formulations

Insulin pump use creates a separate formulation opportunity. A formulation that performs acceptably in a vial or prefilled pen may show different behavior during extended residence in a pump reservoir, tubing, or infusion set.

Key development areas include:

• reduced fibrillation during exposure to heat and agitation;
• lower adsorption to infusion-set materials;
• reduced occlusion risk;
• preservative compatibility;
• improved stability during in-use periods;
• compatibility with automated insulin-delivery systems.

These opportunities may support proprietary formulations, but a formulation change can trigger comparative clinical, device, and regulatory requirements. The commercial advantage must justify the cost of bridging studies and manufacturing validation.

4. Preservative and container-closure alternatives

Metacresol and phenol are effective preservatives but can contribute to local tolerability concerns in sensitive patients. Alternatives or optimized preservative systems may support differentiated products, especially for multidose pens, pump reservoirs, and pediatric products.

Commercial targets include:

• low-extractables elastomer systems;
• preservative-reduced products;
• low-sorption cartridges;
• siliconization systems optimized for insulin;
• cyclic olefin polymer or other low-interaction primary containers;
• prefilled pen components with lower injection force.

The principal barrier is not conceptual formulation design. It is demonstrating that the alternative system preserves potency, sterility, container closure integrity, and in-use stability across the labeled shelf life.

5. Premixed insulin products

Humalog Mix 75/25 and Mix 50/50 use protamine to create a suspension with both rapid and intermediate components. Premix development remains commercially relevant in markets where basal-bolus therapy is less accessible or where simplified regimens are preferred.

Potential improvements include:

• faster and more consistent resuspension;
• reduced settling;
• narrower particle-size distribution;
• improved dose uniformity;
• lower injection volume;
• better stability after repeated pen handling;
• compatibility with lower-cost pen platforms.

Protamine quality is strategically important. Variability in molecular weight distribution, purity, and interaction with insulin can affect suspension characteristics and release behavior.

When does Humalog lose exclusivity?

Humalog’s foundational insulin lispro patents and early formulation protection have expired. The principal commercial barriers are now regulatory approval, manufacturing capability, device development, quality systems, and market access rather than basic patent exclusivity.

The original insulin lispro product was approved in the United States in 1996. The core insulin lispro patent estate was based on patents filed in the early 1990s, placing the earliest composition protection in the early 2010s, subject to patent-term adjustments and any applicable extensions. Those foundational rights no longer prevent biosimilar or follow-on insulin lispro development.

Current risks can still arise from:

• pen and cartridge device patents;
• manufacturing-process patents;
• concentrated formulation patents;
• delivery-enhancing excipient systems;
• method-of-use patents;
• trademarks and trade dress;
• regulatory exclusivity attached to later products;
• patents covering competing products such as Lyumjev.

A competitor should not assume that expired active-ingredient protection eliminates all freedom-to-operate issues. Product-specific device and formulation claims require separate review.

What is the Orange Book and Purple Book status of Humalog?

Humalog is regulated as a biologic insulin product. Biological products are generally evaluated through the Purple Book framework rather than relying on the Orange Book patent-listing model used for conventional small-molecule drugs.

The FDA’s Purple Book identifies reference biological products and biosimilar relationships. Admelog is recognized as a biosimilar to Humalog under the applicable FDA framework. Humalog therefore has a different competitive structure from a small-molecule product with an extensive Orange Book patent listing (FDA, 2024).

For commercial diligence, the relevant questions are:

1. Is the competing insulin lispro product biosimilar or independently licensed?
2. Does it use the same or a different delivery device?
3. Does it rely on a distinct formulation or absorption-enhancing excipient?
4. Does it have interchangeable status?
5. Are device, manufacturing, or method-of-use patents implicated?
6. Does the product require separate clinical bridging for a new concentration or presentation?

Which companies are challenging Humalog commercially?

Sanofi is the clearest direct competitor through Admelog, insulin lispro Sanofi. Novo Nordisk competes with insulin aspart products, including NovoLog and Fiasp. Eli Lilly also competes against its own Humalog franchise through Lyumjev, which uses a faster-acting formulation strategy.

Company	Product	Competitive mechanism
Sanofi	Admelog	Follow-on insulin lispro and price competition
Novo Nordisk	NovoLog/NovoRapid	Alternative rapid-acting insulin analog
Novo Nordisk	Fiasp	Faster absorption through formulation technology
Eli Lilly	Lyumjev	Faster-acting lispro formulation
Regional manufacturers	Insulin lispro and human insulin products	Local pricing, tenders, and supply access

The competitive pressure is strongest in institutional purchasing, government tenders, Medicare-related affordability programs, and markets where biosimilar substitution is permitted.

What patent litigation and settlement risks affect Humalog?

Humalog’s principal market risk is less likely to arise from litigation over the original insulin lispro molecule than from disputes involving later-generation products and delivery systems.

Paragraph IV challenges

Paragraph IV certification is primarily a Hatch-Waxman mechanism for small-molecule products. Because Humalog is a biologic, a competitor typically evaluates the BPCIA biosimilar pathway, patent dance procedures, and biologic patent litigation rather than relying on a conventional Paragraph IV strategy.

A Humalog competitor can still face patent disputes involving:

• insulin analog manufacturing;
• formulation compositions;
• pen injectors;
• cartridges and dose-delivery mechanisms;
• concentrated insulin presentations;
• rapid-absorption excipient systems.

Settlement agreements

Publicly disclosed settlement terms for Humalog-specific biologic disputes are limited compared with major small-molecule generic settlements. Commercial settlements are more likely to involve launch timing, formulation scope, device rights, or manufacturing arrangements than a simple early-entry date based on one Orange Book patent.

How strong is the Humalog patent estate?

The Humalog patent estate is weak for the original insulin lispro and conventional excipient platform because the foundational rights have expired. It remains more relevant for later lifecycle products and delivery technology.

Asset category	Current strategic strength
Insulin lispro active ingredient	Low, foundational protection expired
Glycerol/phosphate/metacresol/zinc platform	Low, conventional and difficult to protect broadly
Humalog U-200 concentration	Moderate, dependent on formulation, device, and implementation claims
Humalog Mix products	Moderate for specific suspension and manufacturing claims
KwikPen and delivery device	Moderate to high depending on claim scope and jurisdiction
Lyumjev absorption-enhancing technology	Stronger than conventional Humalog excipient protection
Manufacturing know-how	Potentially high, but primarily confidential rather than patent-based

The commercial moat is therefore concentrated in manufacturing yield, regulatory history, device integration, supply reliability, payer access, and brand recognition.

What generic or biosimilar launch scenarios exist for Humalog?

Three launch scenarios are commercially realistic.

Low-cost insulin lispro biosimilar

A competitor uses a conventional excipient system and competes primarily on price. This is the most direct route but offers limited differentiation. Success depends on scale, reimbursement, tender access, and device cost.

Device-led follow-on product

A competitor uses a comparable insulin lispro formulation but improves the pen, cartridge, dose accuracy, injection force, or patient access. Device patents and human-factors validation become central.

Formulation-differentiated product

A competitor develops a higher concentration, pump-optimized, faster-acting, or preservative-reduced product. This offers more pricing power but requires greater regulatory investment and may create new patent exposure.

What geographic opportunities exist for Humalog excipients?

The best geographic opportunities are in markets with:

• growing insulin demand;
• local biosimilar incentives;
• government procurement programs;
• limited domestic insulin manufacturing;
• regulatory pathways that accept abridged comparability packages;
• demand for pen, cartridge, or premix presentations.

India, China, Latin America, the Middle East, and selected Southeast Asian markets offer manufacturing and licensing opportunities. European markets have stronger biosimilar infrastructure and established insulin competition. The United States offers the largest value pool but has higher device, quality, reimbursement, and litigation requirements.

Excipient suppliers should prioritize dual sourcing and regional qualification. Insulin production is highly sensitive to supply interruption, and manufacturers increasingly value validated backup sources for preservatives, zinc salts, protamine, container components, and primary packaging.

Key Takeaways

• Humalog uses a mature excipient system built around glycerol, phosphate, metacresol, zinc, and water.
• Premixed Humalog products add protamine to create insulin lispro protamine suspension.
• Original insulin lispro exclusivity has expired; the core formulation is not a strong standalone patent barrier.
• The most attractive opportunities are biosimilar supply, high-concentration insulin, pump-compatible formulations, pen and cartridge systems, and premix stability.
• Admelog is the principal direct follow-on insulin lispro competitor.
• Humalog is assessed primarily through the biologics and Purple Book framework, not a conventional Orange Book strategy.
• Later-generation products such as Lyumjev demonstrate that excipients can support meaningful differentiation.
• Manufacturing control, device integration, regulatory comparability, and supply reliability are more important than broad excipient patent protection.

FAQs

Can metacresol be replaced in a Humalog biosimilar?

Yes, but replacement requires evidence that the alternative preservative maintains antimicrobial effectiveness, insulin stability, potency, container compatibility, and in-use performance.

Is Humalog U-200 protected by a separate patent estate?

Potentially, depending on the specific formulation, pen, cartridge, manufacturing process, and jurisdiction. The original insulin lispro protection does not by itself establish current exclusivity for U-200.

Does protamine create a meaningful barrier for Humalog Mix competitors?

Protamine creates formulation and manufacturing complexity but is not, by itself, a durable exclusivity barrier. Suspension uniformity, resuspension behavior, and dose consistency are the more significant development hurdles.

Which excipient has the highest commercial value in Humalog manufacturing?

No single excipient dominates. Metacresol, zinc, protamine, and primary-container components have high strategic value because changes can materially affect stability, preservation, suspension behavior, and device performance.

Is a Humalog biosimilar automatically interchangeable in the United States?

No. Biosimilarity and interchangeability are distinct regulatory designations. A product must satisfy the FDA’s applicable interchangeability requirements before substitution can occur under state pharmacy laws.

References

1. Eli Lilly and Company. (2024). Annual report 2023.
2. U.S. Food and Drug Administration. (2017). FDA approves Admelog, the first follow-on insulin lispro product.
3. U.S. Food and Drug Administration. (2020). Implementation of the Biologics Price Competition and Innovation Act of 2009.
4. U.S. Food and Drug Administration. (2023a). Humalog insulin lispro injection prescribing information.
5. U.S. Food and Drug Administration. (2023b). Humalog Mix 75/25 and Humalog Mix 50/50 prescribing information.
6. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.